Arcutis Biotherapeutics Hits Day High with Strong 7.29% Intraday Surge

Arcutis Biotherapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 7.29% on September 30, 2025. The stock reached an intraday high of USD 19.36, reflecting strong market activity. Over the past week, Arcutis has outperformed the S&P 500, with a weekly gain of 8.49% compared to the index's decline of 0.49%.
In the last month, the stock has surged by 21.46%, while the S&P 500 has only managed a modest 3.11% increase. Impressively, Arcutis has delivered a remarkable 101.39% return over the past year, significantly surpassing the S&P 500's 16.09% gain. Year-to-date, the stock has risen by 35.32%, again outperforming the broader market.

The company has reported a substantial growth in net sales of 164.13% and has achieved positive results for seven consecutive quarters. With high institutional holdings at 100%, Arcutis benefits from the analytical capabilities of these investors. The stock's performance metrics indicate a strong position within the pharmaceuticals and biotechnology industry, making it a noteworthy player in the market.